Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder Clinical Trial

Official title:
A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Status Terminated

Clinical Trial Summary

To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adjunctive Treatment of Major Depressive Disorder
Depression
Depressive Disorder
Depressive Disorder, Major

Clinical Trial Details

NCT number	NCT04000009
Study type	Interventional
Source	ACADIA Pharmaceuticals Inc.
Contact
Status	Terminated
Phase	Phase 3
Start date	June 6, 2019
Completion date	February 22, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04103892` - A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study	Phase 2
Completed	`NCT03999918` - Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment	Phase 3
Completed	`NCT03018340` - Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)	Phase 2
Completed	`NCT03968159` - Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment	Phase 3